Nivolumab相关论文
目的:通过meta分析评估细胞程序性死亡受体1（programmed cell death protein-1,PD-1）/细胞程序性死亡-配体1（programmed cell death l......
目的 探索EGFR 突变阴性的晚期肺腺癌患者是否可以从应用Nivolumab、阿帕替尼、培美曲塞、顺铂联合治疗在疾病缓解及生存期获益，且......
The excellent effects of Nivolumab alone as third-line therapy for late stage colon cancer with mism
...
目的 免疫检查点抑制剂在治疗晚期肝细胞癌(HCC)的临床试验中取得了丰硕成果1,2,最近nivolumab 已被美国FDA 批准用于晚期肝细胞癌......
The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in
Objective Purpose: Gut microbiome affecting the responses to immune checkpoint inhibitors(ICIs)against advanced non-smal......
How to choose the third-line treatment for advanced gastric or gastroesophageal junction cancer:An i
Objective Although apatinib,immune checkpoint inhibitors,and trifluridine/tipiracil have shown promising results in phas......
...
5-FU-induced up-regulation of exosomal PD-L1 reflects immunosuppression in gastric cancer patients a
Objective Although 5-Fluorouracil(5-FU),an important clinical cytotoxic chemotherapy drug,has been thought to directly k......
Effectiveness and Safety of PD-1 Inhibitors in the Treatment against Solid Tumors: A Systematic Revi
目的 PD-1/PD-L1 inhibitors have been implicated as potentially effective anti-cancer therapies. Some clinical Randomized......
目的 骨肉瘤是儿童、青少年最常见的原发恶性骨肿瘤，易早期发生肺转移，死亡率较高。传统的治疗方式对于进展期和转移的患者疗效不佳，......
Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent SCLC:CA209-032 (N
Objective: Patients (pts) with SCLC respond to initial platinum (PLT) based chemotherapy (CT), but rapidly progress.Comb......
5-Fluorouracil induced up-regulation of exosomal PD-L1-derived from gastric cancer cells causing imm
Objective Although 5-Fluorouracil,as anticancer chemotherapy,has been thought to directly kill cancer cells and improve ......
Clinical response, progression-free survival(PFS), and safety in patients (pts) with advanced melano
Objective: Combined blockade of T-cell checkpoints by NIVO and IPI demonstrated a high objective response rate (ORR), pr......
Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC):association of biom
Objective: This prospective biomarker study in patients (pts) with mRCC treated with the programmed death-1 (PD-1) inhib......
...
Severe Pneumonitis after Nivolumab Treatment Accompanied by Acute Pulmonary Embolism in a Patient wi
...
Unusual Ovarian Cancer Relapse Managed by Nivolumab in a Long-term Surviving Patient with PD-L1 Muta
...
1例82岁女性患者因右肺上叶中心性腺癌多发转移接受纳武利尤单抗单药治疗（240 mg静脉滴注、第1天，14 d为1个周期）。免疫治疗8个周期（约......
Objective: Nivo, a fully human IgG4 programmed death-1 immune checkpoint inhibitor antibody, has demonstrated durabl......
First-line monotherapy with nivolumab (nivo;anti-programmed death-1 [PD-1]) in advanced NSCLCsafety,
Objective: Nivo, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, has demonstrated durable responses an......
目的探讨纳武利尤单抗(Nivo)心脏毒性反应的临床特点。方法检索中国知网、维普、万方、PubMed、Web of Science和MEDLINE数据库(截......
Nivolumab（商品名Opdivo），一种由百时美施贵宝公司研制的单克隆抗体，是程序性死亡受体（PD-1）阻断剂。至2015年10月，FDA已批准其单用或联用......
【摘 要】 近来，一个关于抗宿主对肿瘤反应的分子机制的进展导致了对一种特异性的限定抗肿瘤免疫的监察信号途径的鉴定。一个最重要......
第一部分 TIM-3在肿瘤微环境中的表达及靶向TIM-3抗肿瘤作用机制背景:近年来,肿瘤的免疫治疗取得了令人瞩目的革命性临床效果。尽......
你以前也许未听说过:ipilimumab:与:nivolumab:两个药,不过这2种药物未来将会有效治疗皮肤癌。研究表明,上述两种药物联合使用能够......
[目的]纳武单抗(Nivolumab)为免疫抑制剂中最常用的程序性死亡受体1(PD-1)拮抗剂之一,在带来显著疗效的同时也伴随着部分严重的药......
免疫介导肿瘤治疗是对传统肿瘤学观念的重大革新,也是肿瘤治疗技术的又一突破。免疫介导肿瘤治疗药物在抑制肿瘤细胞生长的同时对......
1 文献来源rn研究一:Hellmann MD,Ciuleanu TE,Pluzanski A,et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor......
Unusual Ovarian Cancer Relapse Managed by Nivolumab in a Long-term Surviving Patient with PD-L1 Muta
...
Impact of previous anti-angiogenesis treatment in nivolumab-treated advanced non-small cell lung can
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
1文献来源Fukuoka S,Hara H,Takahashi N,et al.Regorafenib Plus Nivolumab in Patients WithAdvanced Gastric or Colorectal Ca......
Background:Immunity plays a major role in carcinogenesis and this is the case also for hepatocellular carcinomas(HCC).Ch......
Nivolumab是一种抗PD-1单克隆抗体,用于肿瘤免疫治疗。中南大学湘雅三医院内分泌科收治1例肠癌术后3年的73岁女性患者,用nivolumab......
全球范围内胃癌发病率最高的地区是东亚、南美和中美洲,在日本和韩国胃癌发病率居男性恶性肿瘤首位,在中国胃癌同样是导致癌症相关......
目的:系统评价PD-1抑制剂对比化疗治疗进展期黑色素瘤的有效性和安全性。方法:计算机检索PubMed、EMbase、CNKI、VIP、Wanfang Dat......
肺癌是一种具有侵袭性的疾病,其对化学治疗反应敏感,但复发率高,因此,急需新的治疗策略来延缓肺癌的病程,以弥补化学治疗的不足。......
目的从医疗保健的角度,对纳武利尤单抗治疗铂类化疗失败进展的鳞状或非鳞状非小细胞肺癌(NSCLS)展开药物经济学评价,为国内NSCLS初......
Pericardial Effusion with Tamponade, an Immune-Related Adverse Event Associated with Nivolumab Thera
Immune checkpoint inhibitors have shown to be very effective when treating lung cancer. Nivolumab, a programmed death-1 ......
Treatment of Skin Reaction Induced by Nivolumab Combined with Radiotherapy in Non-small Cell Lung Ca
Skin reaction or dermatological toxicities induced by immunotherapy is common.It usually manifests skin rash or erythema......
BACKGROUND A variety of immune-modulating drugs are becoming increasingly used for various cancers.Despite increasing in......
With the recent development and clinical application, immune checkpoint inhibitors (ICIs) intervention is being increasi......
Introduction: Immunotherapy is also called as biologic therapy or bio-therapy. Immunotherapy is quickly becoming an impo......
Prognostic and Predictive Value of Pretreatment Derived Neutrophil-to-Lymphocyte Ratio in Non-Small-
Background: Immune checkpoint inhibitors produce prolonged responses in select non-small cell lung cancer (NSCLC) patien......
Translating new data to the daily practice in second line treatment of renal cell carcinoma:The role
The therapeutic options for patients with metastatic renal cell carcinoma(mRCC)have completely changed during the last t......
Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient
BACKGROUND Dual checkpoint inhibition improves response rates in treatment naive patients with metastatic melanoma compa......
BACKGROUND Checkpoint-Inhibition has revolutionized the treatment for several entities such as melanoma and renal cell c......
Immunotherapy is any treatment aimed at boosting or enhancing the immune system.It includes a wide range of options,from......
Hepatocellular carcinoma(HCC)is the fifth leading cause of cancer mortality in the United States and the second leading ......
